Harrow Re-Launches Steroid-Sparing VERKAZIA For Vernal Keratoconjunctivitis, Targeting Underlying Inflammatory Mechanisms In Pediatric Patients
Harrow, Inc.
Harrow, Inc. HROW | 0.00 |
- VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriers
- VERKAZIA is indicated for the treatment of all forms of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children and may lead to sight-threatening conditions if left untreated or undertreated
- VERKAZIA is a calcineurin inhibitor immunomodulator that targets the underlying inflammatory mechanisms of VKC and may reduce the need for steroid rescue, all of which are associated with risks such as glaucoma or cataract formation